MYD88 and diffuse large B-cell lymphoma: In addition, a retrospective study conducted in China demonstrated that MYD88-mutated DLBCL patients exhibited lower survival outcomes, with 3-year and 5-year OS of 20.69% and 7.89%, respectively [14].